XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties Dec 19, 2023 7:30am EST
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value Nov 07, 2023 7:30am EST
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) Oct 31, 2023 7:30am EDT
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy Aug 08, 2023 7:30am EDT
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset Jun 22, 2023 7:30am EDT
